Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. INmune Bio, Inc.
  6. Summary
    INMB   US45782T1051

INMUNE BIO, INC.

(INMB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/30/2021 05/03/2021 05/04/2021 05/05/2021 05/06/2021 Date
11.87(c) 11.95(c) 11.15(c) 11.07(c) 10.46(c) Last
53 118 61 752 99 877 71 974 273 613 Volume
+1.02% +0.67% -6.69% -0.72% -5.51% Change
More quotes
Financials (USD)
Sales 2021 - - -
Net income 2021 -19,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,67x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -33,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,17x
Yield 2022 -
Capitalization 156 M 156 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 5
Free-Float 49,5%
More Financials
Company
Inmune Bio Inc. is a clinical-stage pharmaceutical immunotherapy company. The Company is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells).... 
More about the company
Notations Surperformance© of INmune Bio, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about INMUNE BIO, INC.
05/06INMUNE BIO, INC.  : Results of Operations and Financial Condition, Financial Sta..
AQ
05/05INMUNE BIO  : Management's Discussion and Analysis of Financial Condition and Re..
AQ
05/05INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business U..
GL
04/29INMUNE BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/28INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a..
GL
04/27INMUNE BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/26INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neur..
GL
04/21INMUNE BIO  : B. Riley Starts INmune Bio at Buy with $29 PT; Says Breast Cancer,..
MT
04/14INMUNE BIO, INC.  : Termination of a Material Definitive Agreement (form 8-K)
AQ
03/29INMUNE BIO, INC.  : Entry into a Material Definitive Agreement, Other Events, Fi..
AQ
03/23INMUNE BIO, INC.  : Other Events (form 8-K)
AQ
03/22INMUNE BIO, INC.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/22INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presen..
GL
03/16INMUNE BIO, INC.  : Other Events (form 8-K)
AQ
03/15INMUNE BIO  : Files Shelf for Up to $250 Million in Securities
MT
More news
News in other languages on INMUNE BIO, INC.

- No features available -

More news
Analyst Recommendations on INMUNE BIO, INC.
More recommendations
Chart INMUNE BIO, INC.
Duration : Period :
INmune Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INMUNE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 29,50 $
Last Close Price 10,46 $
Spread / Highest target 206%
Spread / Average Target 182%
Spread / Lowest Target 149%
EPS Revisions
Managers and Directors
NameTitle
Raymond J. Tesi Chairman, President, Chief Executive Officer & CMO
David J. Moss Chief Financial Officer, Secretary & Treasurer
Mark Lowdell Chief Scientific & Manufacturing Officer
J. Kelly Ganjei Independent Director
Timothy J. Schroeder Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INMUNE BIO, INC.-39.26%156
GILEAD SCIENCES, INC.14.16%83 740
WUXI APPTEC CO., LTD.10.67%59 429
VERTEX PHARMACEUTICALS-9.81%55 364
REGENERON PHARMACEUTICALS-0.14%49 948
BIONTECH SE106.08%41 245